Gonadorelin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Gonadorelin

Also known as: GnRH, LH-RH, LHRH, Gonadotropin-Releasing Hormone, Gonadorelin Hydrochloride, Gonadorelin Acetate, Gonadorelin Diacetate Tetrahydrate, Factrel

Peptide hormone / Gonadotropin-Releasing Hormone (GnRH) agonist (native decapeptide)

Research chemicalLast updated: October 31, 2026Based on 20 peer-reviewed studies

What it is

Gonadorelin is the synthetic form of the natural hormone that triggers the pituitary to release sex hormones; it's used in fertility treatment and diagnostic testing. It works by pulsing the pituitary to stimulate the hormones that drive testosterone and estrogen production. Not FDA-approved as a standalone therapeutic drug; banned by WADA in sport.

The scientific side

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH), synthesized and released by the hypothalamus. It regulates the production and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the anterior pituitary (adenohypophysis). When administered parenterally, it was initially used diagnostically as a test of pituitary reserve of LH and FSH; subsequently, native GnRH was used therapeutically to treat hypothalamic hypogonadal and infertility states. In male athletes, its misuse triggers testosterone increase, which is why WADA has banned it. In aquaculture studies, gonadorelin has been shown to increase circulating concentrations of sex steroids (17β-estradiol, 17α-hydroxyprogesterone, testosterone) and modulate gonadotropin expression, and was associated with ovulation in female tambaqui fish. In dairy cattle, gonadorelin stimulates LH release leading to ovulation, and its effects are dose-dependent.

Class: Peptide hormone / Gonadotropin-Releasing Hormone (GnRH) agonist (native decapeptide)

Administration & storage

Administration
Intravenous (i.v.) — used in diagnostic GnRH stimulation tests in humans (PMID: 3103350)Intravenous — case report of anaphylaxis after i.v. gonadorelin acetate (PMID: 26197466)Intranasal spray — used for cryptorchidism treatment in children (PMID: 2572057; PMID: 35691791)Pulsatile subcutaneous/intravenous infusion pump — used for hypogonadotropic hypogonadism treatment in men (PMID: 30569789; PMID: 25131486)Infusion pump (IgE-mediated hypersensitivity case) — pump delivery reported in female patient with hypogonadotropic hypogonadism (PMID: 2653043)Veterinary intramuscular or i.v. injection (not specified route) — used in Ovsynch cattle protocols (PMID: 25979657; PMID: 41698585; PMID: 39603499)
Storage
No storage conditions for gonadorelin are explicitly described in the reviewed abstracts.
Cautions
Severe anaphylaxis has been reported following intravenous gonadorelin acetate administration; gonadorelin should only be administered in a setting equipped to manage systemic reactions.,IgE-mediated hypersensitivity (wheal-and-flare at injection sites, elevated IgE antibodies to gonadorelin) was reported in a patient receiving long-term gonadorelin hydrochloride (Factrel) via infusion pump.,Skin allergic erythema scleroma was a common reported side effect at the site of the pulsatile gonadorelin pump in men with CHH.,Long-term treatment with gonadorelin agonist analogs (e.g., triptorelin) has been associated with significant bone loss/osteoporosis; this adverse effect warrants monitoring (PMID: 17971105; PMID: 17290340).,Gonadorelin is listed as a banned substance by WADA; its use by athletes for testosterone enhancement is considered doping.,Sterile technique is essential for any injectable peptide preparation to prevent contamination and infection at injection sites.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Listed as a banned substance in sports per WADA (PMID: 35028691; PMID: 36858006)

Health Canada

Not stated in reviewed literature — requires manual verification